DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT04873245

QUEST

Active not recruitingPhase 2

Lifestyle Counseling and Medication for Adolescent Weight Management

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

120

actual

Study population

Obesity / overweight

Key I/E criterion

•Age 12-17

Primary endpoint

•BMI, change

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT04873245
Org study IDPEDS-2021-29784

Timeline

Milestones

Study first posted2021-05-05actual
Study start2022-03-15actual
Last update posted2026-05-19actual
Primary completion2026-06-30estimated
Study completion2027-06-30estimated

Assets

Investigational agents

Semaglutide

Study populations

Who this study enrolls

Obesity / overweight

Eligibility

Who can enroll

Minimum age12 Years
Maximum age17 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Obesity (Body Mass Index (BMI) >/= 95th percentile or BMI >/= 30 kg/m2)
•Age 12 to < 18 years old and Tanner stage >1

Exclusion criteria

•Diabetes (type 1 or 2)
•Current or recent (< 6 months prior to enrollment) use of anti-obesity medication(s) defined as orlistat, phentermine, topiramate, combination phentermine/topiramate, liraglutide (or other GLP-1RA) and/or combination naltrexone/bupropion (monotherapy use of naltrexone or bupropion is not an exclusion)
•Previous bariatric surgery
•Any history of treatment with growth hormone
•Medically-documented history of bulimia nervosa
•Any history of schizophrenia, psychosis, mania, chemical dependency
•Unstable depression requiring hospitalization within the previous 6 month
•Any history of suicide attempt
•History of suicidal ideation or self-harm within the previous 30 days as determined at screening by a PHQ-9 score >/= 15 or Suicidal ideation of type 4 or 5 on the C-SSRS
•Current pregnancy or plans to become pregnant
•ALT or AST >/= 5 times the upper limit of normal
•Creatinine > 1.2 mg/dL
•Uncontrolled hypertension as determined by the local medical monitor
•Diagnosed and medically-documented monogenic obesity
•Medically-documented history of cholelithiasis
•Untreated thyroid disorder
•Medically documented history of pancreatitis
•Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2
•Clinically significant heart disease as determined by the local medical monitor
•Personal history of malignant neoplasms within the past five years
•Hypersensitivity to any component of semaglutide

Endpoints (1)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Weight & body composition

1 endpoint
Primary/protocol endpoint

Change in body mass index

Time frame:52 weeks

BMI, change

percent change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.